Results Fom Probi's Clinical Studies in Immune and Gut Health

LUND, Sweden--(BUSINESS WIRE)--Regulatory News: The results from Probi’s (STO:PROB) two clinical studies conducted in 2012, one in immune health and one in gut health, are now available. Preliminary analyses of the data show that the results from the studies did not meet expectations. Probi will consequently not apply to the European Food Safety Authority (EFSA) for health claims within the EU at this point. ”We have gained important new knowledge from the studies and the data will now be analysed in more detail to guide continued clinical development within immune and gut health, areas where we have previously demonstrated very good results”, says Michael Oredsson, CEO at Probi.